<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852694</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01</org_study_id>
    <nct_id>NCT02852694</nct_id>
  </id_info>
  <brief_title>Reduce Risk for Crohn's Disease Patients</brief_title>
  <acronym>RCT</acronym>
  <official_title>Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PIBD-Net</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PIBD-Net</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of weekly subcutaneously
      administered Methotrexate for maintaining relapse-free sustained steroid/Enteral Nutrition
      -free 1-year remission compared with:

        -  daily oral Azathioprine / 6 mercaptopurine in low risk paediatric Crohn's disease

        -  subcutaneously administered adalimumab in high risk paediatric Crohn's disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized controlled trial PIBDNet (pediatric inflammatory bowel diseases network)
      aims to compare the following treatment strategy by dividing patients into two risk groups
      for aggressive disease evolution: the effectiveness of Methotrexate versus Azathioprine / 6
      mercaptopurine for the maintenance of remission in Crohn's disease in children who are at low
      risk for aggressive disease and the effectiveness of Methotrexate versus adalimumab in the
      high risk group. PIBDNet hypothesizes that Methotrexate is superior to Azathioprine / 6
      mercaptopurine for maintaining remission in Crohn's disease in the low risk strata and
      adalimumab is superior to Methotrexate in the high risk strata. In addition, the ancillary
      study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus
      patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of sustained steroid/EEN-free remission at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Rate of sustained steroid/EEN-free remission at Month 12, where sustained remission is defined as wPCDAI (weighted pediatric crohn disease activity index) ≤12.5 and CRP ≤1,5 fold the normal upper limit without a relapse since week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>Month 12</time_frame>
    <description>the goal is to compare the time of the first relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission at 12 weeks (measured by wPCDAI&lt;/=12.5 and normal CRP and being off steroids/exclusive enteral nutrition)</measure>
    <time_frame>12 weeks</time_frame>
    <description>the goal is to compare the remission at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linear height velocity</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to compare linear height velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of protocol drug methotrexate by blood methotrexate assessments</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to compare toxicity of protocol drug methotrexate by blood methotrexate assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of protocol drug adalimumab by blood adalimumab assessments</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to compare toxicity of protocol drug adalimumab by blood adalimumab assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of protocol drug 6 mercaptopurine by blood 6 mercaptopurine assessments</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to compare toxicity of protocol drug 6 mercaptopurine by blood 6 mercaptopurine assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of protocol drug azathioprine by blood azathioprine assessments</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to compare toxicity of protocol drug azathioprine by blood azathioprine assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire : health-related life of quality (IMPACT 3) between the different treatment arms</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to compare health-related life of quality (IMPACT 3) between the different treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of methotrexate in case of therapy failure based on physiological parameters, questionnaires</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate effectiveness of methotrexate in case of therapy failure based on physiological parameters, questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of adalimumab in case of therapy failure based on physiological parameters, questionnaires</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate effectiveness of adalimumab in case of therapy failure based on physiological parameters, questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of azathioprine in case of therapy failure based on physiological parameters, questionnaires</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate effectiveness of azathioprine in case of therapy failure based on physiological parameters, questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of 6 mercaptopurine in case of therapy failure based on physiological parameters, questionnaires</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate effectiveness of 6 mercaptopurine in case of therapy failure based on physiological parameters, questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomic predictors for response by measuring physiological parameters</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate genomic predictors for response by measuring physiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological markers predictors for response by measuring physiological parameters such as ASCA (anti saccharomyces cerevisiae antibody)</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate serological markers predictors for response by measuring physiological parameters such as ASCA (anti saccharomyces cerevisiae antibody)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of fecal calprotectin levels</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate predictive value of fecal calprotectin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of CRP</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate predictive value of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire : TUMMY-CD (patient reported outcome) methotrexate treated patients at month 12</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate questionnaire : TUMMY-CD (patient reported outcome) methotrexate treated patients at month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire : TUMMY-CD (patient reported outcome) adalimumab treated patients at month 12</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate questionnaire : TUMMY-CD (patient reported outcome) adalimumab treated patients at month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire : TUMMY-CD (patient reported outcome) 6 mercaptopurine treated patients at month 12</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate questionnaire : TUMMY-CD (patient reported outcome) 6 mercaptopurine treated patients at month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire : TUMMY-CD (patient reported outcome) azathioprine treated patients at month 12</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate questionnaire : TUMMY-CD (patient reported outcome) azathioprine treated patients at month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA (desoxy ribonucleic acid) pharmacogenetics (multiplex genotyping of polymorphism in drug metabolism) for methotrexate in relation to toxicity and response to therapy</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate DNA pharmacogenetics (multiplex genotyping of polymorphism in drug metabolism) for methotrexate in relation to toxicity and response to therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA pharmacogenetics (multiplex genotyping of polymorphism in drug metabolism) for 6 mercaptopurine in relation to toxicity and response to therapy</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate DNA pharmacogenetics (multiplex genotyping of polymorphism in drug metabolism) for 6 mercaptopurine in relation to toxicity and response to therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA pharmacogenetics (multiplex genotyping of polymorphism in drug metabolism) for azathioprine in relation to toxicity and response to therapy</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate DNA pharmacogenetics (multiplex genotyping of polymorphism in drug metabolism) for azathioprine in relation to toxicity and response to therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of methotrexate drug monitoring in relation to adherence, toxicity and response</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate concentration of methotrexate drug monitoring in relation to adherence, toxicity and response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of adalimumab drug monitoring in relation to adherence, toxicity and response</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate concentration of adalimumab drug monitoring in relation to adherence, toxicity and response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Mercaptopurine metabolites monitoring : concentration of metabolites in relation to adherence, toxicity and response</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate 6 Mercaptopurine metabolites monitoring : concentration of metabolites in relation to adherence, toxicity and response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>azathioprine metabolites monitoring : concentration of metabolites in relation to adherence, toxicity and response</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate azathioprine metabolites monitoring : concentration of metabolites in relation to adherence, toxicity and response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-adalimumab antibodies monitoring : concentration of anti-adalimumab antibodies in relation to adherence, toxicity and response</measure>
    <time_frame>12 months</time_frame>
    <description>the goal is to evaluate anti-adalimumab antibodies monitoring : concentration of anti-adalimumab antibodies in relation to adherence, toxicity and response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>High Risk Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous methotrexate versus subcutaneous adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ancillary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children &lt;20kg: 1x 5mg) is recommended.</description>
    <arm_group_label>High Risk Group</arm_group_label>
    <arm_group_label>Low risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients &lt; 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.</description>
    <arm_group_label>High Risk Group</arm_group_label>
    <arm_group_label>Ancillary</arm_group_label>
    <other_name>humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine / 6 Mercaptopurine</intervention_name>
    <description>Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.</description>
    <arm_group_label>Low risk group</arm_group_label>
    <other_name>imurel / purinethol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children 6-17, with a new-onset Crohn Disease diagnosed using established criteria
             (37, 38), requiring a steroid-based or Enteral nutrition based induction therapy

          2. At initial diagnosis, wPCDAI &gt;40 or CRP&gt;2 times upper limit at diagnosis

          3. all wPCDAI scores (0-120) are possible at inclusion (patients in remission and
             patients with active disease)

          4. Luminal active Crohn Disease (B1) with or without B2 and/or B3 disease behavior

          5. Initial exposure to 5-ASA and derivate is tolerated

          6. Exposure to antibiotics is tolerated

          7. If one of the following criteria is present, patients are allocated to the high risk
             group prior randomization:

               -  Complex fistulizing perianal disease

               -  Panenteric disease phenotype (defined as L3 with L4b per Paris classification or
                  L3 with deep ulcers in duodenum, stomach or oesophagus (not HP (helicobacter
                  pylori)- or NSAID-related))

               -  Severe growth impairment (height z-score &lt;-2 or crossing 2 percentiles or more)
                  likely related to CD

               -  Significant hypoalbuminemia (&lt;30g/l), elevated C reactive protein (CRP) (at least
                  2 times above normal range), or wPCDAI &gt;12.5 despite 3 weeks of optimized
                  induction therapy with steroids or Exclusive enteral nutrition

               -  B2, B3 or B2B3 disease behavior

               -  Overall cumulative disease extend of ≥60 cm

          8. Informed and signed consent

        Exclusion Criteria:

          1. Patients with wPCDAI&lt;42,5 at initial diagnosis, except if CRP&gt;2 times upper limit

          2. No induction therapy with steroids or enteral nutrition

          3. Previous therapy with any IBD (inflammatory bowel desease) -related medications other
             than induction therapy as detailed in this protocol (except 5-ASA).

          4. Pregnancy or refusal to use contraceptives during the study period in pubertal
             patients (both boys and girls) unless absolute abstinence (no sexual activity) is
             confirmed at each study visit. Positive pregnancy testing throughout the study will
             trigger prompt withdrawal of the patient from the study.

          5. Lactating mothers

          6. Children with perianal fistulising disease who require surgical therapy (drainage,
             seton placement)

          7. Patients homozygous for Thiopurine methyl transferase or those with Thiopurine methyl
             transferase activity &lt;6 nmol/h/ml erythrocytes or &lt;9nmol 6MTG (6 methylthioguanine/g
             Hb/h), unless they qualify as high risk patients

          8. Evidence of un-drained and un-controlled abscess/phlegmon

          9. Contraindication to any drugs used in the trial (including
             intolerance/hypersensitivity or allergy to either study drug (thiopurines,
             methotrexate or adalimumab))

         10. Current or previous malignancy

         11. Serious comorbidities (such as renal insufficiency, hepatitis, respiratory
             insufficiency) interfering with drug therapy or interpretation of outcome parameters
             or will make it unlikely that the patients will finish the trial.

         12. Infection with mycobacterium tuberculosis

         13. Moderate to severe heart failure (NYHA classe III/IV)

         14. Oral anticoagulant therapy, anti-malaria therapy

         15. Live vaccines exposure (including yellow fever) less than 3 weeks prior inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank RUEMMELE, PhD / MD</last_name>
    <role>Study Director</role>
    <affiliation>PIBD-Net</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sandrine ROUX, MSc</last_name>
    <phone>+33144492572</phone>
    <email>sroux@pibd-net.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>marie jo BERTIN</last_name>
    <phone>+33680476085</phone>
    <email>mjbertin@pibd-net.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker -Enfants Malades (Service de gastro-enterologie)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank RUEMMELE, MD</last_name>
      <phone>+33 (0)144492516</phone>
      <email>frank.ruemmele@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;(2):CD000067. Review. Update in: Cochrane Database Syst Rev. 2009;(1):CD000067.</citation>
    <PMID>10796482</PMID>
  </reference>
  <reference>
    <citation>Faubion WA Jr, Bousvaros A. Medical therapy for refractory pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2006 Oct;4(10):1199-213. Epub 2006 Jul 26. Review.</citation>
    <PMID>16872913</PMID>
  </reference>
  <reference>
    <citation>Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995 Nov;37(5):674-8.</citation>
    <PMID>8549944</PMID>
  </reference>
  <reference>
    <citation>Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000 Oct;119(4):895-902.</citation>
    <PMID>11040176</PMID>
  </reference>
  <reference>
    <citation>D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999 Nov;50(5):667-71.</citation>
    <PMID>10536324</PMID>
  </reference>
  <reference>
    <citation>Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014 Jan;109(1):23-34; quiz 35. doi: 10.1038/ajg.2013.402. Epub 2013 Dec 10.</citation>
    <PMID>24322839</PMID>
  </reference>
  <reference>
    <citation>Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M; AZTEC Study Group. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology. 2013 Oct;145(4):766-74.e1. doi: 10.1053/j.gastro.2013.06.009. Epub 2013 Jun 13.</citation>
    <PMID>23770132</PMID>
  </reference>
  <reference>
    <citation>Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology. 2013 Oct;145(4):758-65.e2; quiz e14-5. doi: 10.1053/j.gastro.2013.04.048. Epub 2013 Apr 30.</citation>
    <PMID>23644079</PMID>
  </reference>
  <reference>
    <citation>Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003459. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD003459.</citation>
    <PMID>15674908</PMID>
  </reference>
  <reference>
    <citation>Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000 Jun 1;342(22):1627-32.</citation>
    <PMID>10833208</PMID>
  </reference>
  <reference>
    <citation>Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995 Feb 2;332(5):292-7.</citation>
    <PMID>7816064</PMID>
  </reference>
  <reference>
    <citation>Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989 Mar 1;110(5):353-6.</citation>
    <PMID>2492786</PMID>
  </reference>
  <reference>
    <citation>Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Böcker U, Böhm S, Büning C, Duchmann R, Gerken G, Herfarth H, Lügering N, Kruis W, Reinshagen M, Schmidt J, Stallmach A, Stein J, Sturm A, Galle PR, Hommes DW, D'Haens G, Rutgeerts P, Neurath MF. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci. 2006 Sep;51(9):1516-24. Epub 2006 Aug 22.</citation>
    <PMID>16927148</PMID>
  </reference>
  <reference>
    <citation>Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y; Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005 Jun;128(7):1812-8.</citation>
    <PMID>15940616</PMID>
  </reference>
  <reference>
    <citation>Lémann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000 Jul;95(7):1730-4.</citation>
    <PMID>10925976</PMID>
  </reference>
  <reference>
    <citation>Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis. 2003 Sep;35(9):619-27.</citation>
    <PMID>14563183</PMID>
  </reference>
  <reference>
    <citation>Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin H, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997 Dec;92(12):2203-9. Erratum in: Am J Gastroenterol. 2015 Apr;110(4):608. Shirin, C [corrected to Shirin, H].</citation>
    <PMID>9399753</PMID>
  </reference>
  <reference>
    <citation>Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Apr;44(4):427-30.</citation>
    <PMID>17414138</PMID>
  </reference>
  <reference>
    <citation>Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr. 1998 May;132(5):830-5.</citation>
    <PMID>9602195</PMID>
  </reference>
  <reference>
    <citation>Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cézard JP, Turck D, Ruemmele FM. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis. 2006 Nov;12(11):1053-7.</citation>
    <PMID>17075346</PMID>
  </reference>
  <reference>
    <citation>Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol. 2007 Dec;102(12):2804-12; quiz 2803, 2813.</citation>
    <PMID>18042110</PMID>
  </reference>
  <reference>
    <citation>Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. Epub 2006 Dec 3.</citation>
    <PMID>17324398</PMID>
  </reference>
  <reference>
    <citation>Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y, Huang B, Bittle B, Marshall M, Lazar A. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012 Aug;143(2):365-74.e2. doi: 10.1053/j.gastro.2012.04.046. Epub 2012 May 2.</citation>
    <PMID>22562021</PMID>
  </reference>
  <reference>
    <citation>D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9.</citation>
    <PMID>18295023</PMID>
  </reference>
  <reference>
    <citation>Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012 Jul;18(7):1340-55. doi: 10.1002/ibd.21903. Epub 2011 Nov 8. Review.</citation>
    <PMID>22069240</PMID>
  </reference>
  <reference>
    <citation>North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America, Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, Griffiths AM, Jevon GP, Higuchi LM, Hyams JS, Kirschner BS, Kugathasan S, Baldassano RN, Russo PA. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74.</citation>
    <PMID>17460505</PMID>
  </reference>
  <reference>
    <citation>Winther KV, Føgh P, Thomsen OØ, Brynskov J. Inflammatory bowel disease (ulcerative colitis and Crohn's disease): diagnostic criteria and differential diagnosis. Drugs Today (Barc). 1998 Nov;34(11):935-42.</citation>
    <PMID>14743262</PMID>
  </reference>
  <reference>
    <citation>Rosh JR. Methotrexate. In: Mamula P, Baldassano RN, Markowitz JE, editors. Pediatric inflammatory bowel disease2007. p. In press.</citation>
  </reference>
  <reference>
    <citation>Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J, Buderus S, Martín-de-Carpi J, De Ridder L, Fagerberg UL, Hugot JP, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López VM, Paerregaard A, Russell RK, Serban DE, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D; European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014 Oct;8(10):1179-207. doi: 10.1016/j.crohns.2014.04.005. Epub 2014 Jun 6.</citation>
    <PMID>24909831</PMID>
  </reference>
  <reference>
    <citation>Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007 Aug;133(2):412-22. Epub 2007 Jun 2.</citation>
    <PMID>17681162</PMID>
  </reference>
  <reference>
    <citation>Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008 Oct;135(4):1106-13. doi: 10.1053/j.gastro.2008.06.079. Epub 2008 Jul 3.</citation>
    <PMID>18692056</PMID>
  </reference>
  <reference>
    <citation>Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008 Oct;135(4):1114-22. doi: 10.1053/j.gastro.2008.06.081. Epub 2008 Jul 3.</citation>
    <PMID>18725221</PMID>
  </reference>
  <reference>
    <citation>Pigneur B, Escher J, Elawad M, Lima R, Buderus S, Kierkus J, Guariso G, Canioni D, Lambot K, Talbotec C, Shah N, Begue B, Rieux-Laucat F, Goulet O, Cerf-Bensussan N, Neven B, Ruemmele FM. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013 Dec;19(13):2820-8. doi: 10.1097/01.MIB.0000435439.22484.d3.</citation>
    <PMID>24216686</PMID>
  </reference>
  <reference>
    <citation>Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, Ruemmele FM, Cosnes J. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010 Jun;16(6):953-61. doi: 10.1002/ibd.21152.</citation>
    <PMID>19834970</PMID>
  </reference>
  <reference>
    <citation>Ruemmele FM, Lachaux A, Cézard JP, Morali A, Maurage C, Giniès JL, Viola S, Goulet O, Lamireau T, Scaillon M, Breton A, Sarles J; Groupe Francophone d'Hépatologie, Gastroentérologie et Nutrition Pédiatrique. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis. 2009 Mar;15(3):388-94. doi: 10.1002/ibd.20788.</citation>
    <PMID>19023899</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, Rosh JR, Ruemmele FM, Awni WM. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015 Apr;21(4):783-92. doi: 10.1097/MIB.0000000000000327.</citation>
    <PMID>25723614</PMID>
  </reference>
  <reference>
    <citation>Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3.</citation>
    <PMID>26342731</PMID>
  </reference>
  <reference>
    <citation>Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.</citation>
    <PMID>20393175</PMID>
  </reference>
  <reference>
    <citation>Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, Van Assche G, Lee JC, Lindsay JO, Rubin DT, Panaccione R, Colombel JF. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec;10(12):1385-1394. Epub 2016 Jun 9. Erratum in: J Crohns Colitis. 2016 Dec;10 (12 ):1457.</citation>
    <PMID>27282402</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

